[(2R)-3-[hydroxy-[2-[[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]amino]ethoxy]phosphoryl]oxy-2-octadecanoyloxypropyl] (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [(2R)-3-[hydroxy-[2-[[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]amino]ethoxy]phosphoryl]oxy-2-octadecanoyloxypropyl] (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
• 化学式: C₆₃H₁₀₈NO₉P
• 分子量: 1054.5
• InChiKey: ADDPEZRSZBDOJY-BVOFIPPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  19.6
• 重原子数：
  74
• 可旋转键数：
  56
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• NUTRITIONAL COMPOSITIONS CONTAINING A NEUROLOGIC COMPONENT AND USES THEREOF
  申请人：MJN U.S. Holdings, LLC

  公开号：EP2943079A1

  公开（公告）日：2015-11-18
• NUTRITIONAL COMPOSITIONS CONTAINING AN ELEVATED LEVEL OF INOSITOL AND USES THEREOF
  申请人：MJN U.S. Holdings LLC

  公开号：EP3302102A1

  公开（公告）日：2018-04-11
• [EN] NUTRITIONAL COMPOSITIONS CONTAINING A NEUROLOGIC COMPONENT AND USES THEREOF<br/>[FR] COMPOSITIONS NUTRITIONNELLES CONTENANT UN COMPOSANT NEUROLOGIQUE ET LEURS UTILISATIONS
  申请人：MJN US HOLDINGS LLC

  公开号：WO2014109862A1

  公开（公告）日：2014-07-17

  The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.
• [EN] NUTRITIONAL COMPOSITIONS CONTAINING AN ELEVATED LEVEL OF INOSITOL AND USES THEREOF<br/>[FR] COMPOSITIONS NUTRITIONNELLES CONTENANT UN NIVEAU ÉLEVÉ D'INOSITOL, ET LEURS UTILISATIONS
  申请人：MJN US HOLDINGS LLC

  公开号：WO2016195888A1

  公开（公告）日：2016-12-08

  A method for enhancing neurological health and development in a subject involving administering to the subject a nutritional composition including no greater than about 7 g/100 kcal of a fat or lipid source; no greater than about 7 g/100 kcal of a protein or protein equivalent source; at least about 5 g/100 kcal of a carbohydrate; and at least about 9 mg/100 kcal of inositol, wherein the ratio of exogenous inositol to inherent inositol is at least 50:50.